Replies to post #20405 on Humanigen Inc (fka HGENQ)

[rstar]

great article, wonderful first person experience:

While it is not clear which treatment group Marc was assigned to, within 24 hours after receiving the study drug, his symptoms dramatically improved and within about a week, he was discharged from the hospital and has since made a full recovery.

https://www.augustachronicle.com/ZZ/sponsored/20201019/recovered-covid-19-patient-urges-others-to-participate-in-clinical-trials

“To recover from this pandemic we will need therapeutics, combination approaches and vaccines,” said Cameron Durrant, MD, MBA, chief executive officer of Humanigen, the biopharmaceutical company developing lenzilumab. “When it comes to COVID-19, we believe that having a therapeutic, like lenzilumab, that may reduce the time to recovery and possibly send patients home earlier, is a near-term solution that has the potential to be a game-changer in the face of this pandemic.”

[Knuckle Sandwich]

That is really impressive, we need that Phase III Data now!

Baranski was enrolled into the study according to the clinical trial protocol (which is randomized, meaning there is a 50/50 chance he was dosed with either lenzilumab or placebo) shortly after being transferred to St. Barnabas. It is important to note that all subjects participating in this study are able to receive other COVID-19 therapies that are considered standard of care. While it is not clear which treatment group Marc was assigned to, within 24 hours after receiving the study drug, his symptoms dramatically improved and within about a week, he was discharged from the hospital and has since made a full recovery.